

# Phytochemicals for Cancer Treatment: An Update on Plant-Derived Anti-cancer Compounds and Their Mechanisms of Action


Sana Ullah<sup>1</sup>, Muhammad Ali<sup>1</sup>,  
Tariq Khan<sup>1</sup>

<sup>1</sup>Department of Biotechnology, Quaid-I-Azam University, Islamabad


## ABSTRACT

Cancer is caused by the combined effect of different factors that act sequentially and simultaneously however, its treatment through conventional approaches comes with several pitfalls and severe side effects such as toxicity to normal cells, inadequate bioavailability, fast clearance, non-specificity as well as high cost. In contrast, plant-based anticancer agents have natural characteristics that can circumvent such limitations as they are comparatively more potent, safer, easily available and cheaper. The current review focuses on the results of selected plant-based anticancer compounds extracted in their pure form and used solely for assessment of anticancer potential through standardized approaches. The probable mechanisms of action of these compounds include inhibition of cancer cell growth, inhibition of tumor growth, cytotoxicity to cancerous cells, inhibition of angiogenesis, induction of apoptosis, caspases stimulation, degradation of mitochondrial membrane, stimulation of apoptotic proteins, inhibition of topoisomerase, reduction of cell viability and arresting of cell cycle progression. However, these preliminary testing is not enough for the approval of these compounds as an anticancer agents. Further research is required to characterize and screen these potential drug candidates against a wide range of in vitro and proper in vivo system to confirm their safety and potency for the cancer treatment.

**Keywords:** Cancer, plants, apoptosis, phytochemicals, stimulation, inhibition, potent, anticancer agents.




Plant mediated anticancer compounds reduces tumor growth and progression *in vivo*. Phytochemicals compounds inhibit angiogenesis, reduce cancer cell viability, inhibit growth and arrest cell cycle progression. They can also confer apoptosis in cancerous cells by means of nuclear fragmentation, chromatin condensation and membrane blebbing.




**Figure 1.** Schematic representation of Albanol A treatment on HL60 cells.

- 1) Albanol A has a potency of reducing the expression level of procaspases-3, 8, and 9 in time reliant manner.
- 2) Albanol A can reduce the expression of Bcl-2 (anti-apoptotic protein) and Bid expression level (proapoptotic proteins), in time-dependent manner.




**Figure 2.** Schematic representation of oridonin treatment on NOZ cells.

Tumor xenograft models can be established through subcutaneous injection of NOZ cells into a mice. Oridonin treatment can predominantly inhibit tumor xenografts formation.



**Figure 3.** Schematic representation of deoxyelephantopin treatment on EAC cells.

(1) Apoptotic activities/indicators in the form of morphological alteration occur in the treated cells such as nuclear fragmentation, (2) chromatin condensation and (3) membrane blebbing.



**Figure 4.** Chemical structures of the anticancer compounds. (A), Kaempferol, (B), Baicalin, (C), Gallic acid, (D), Andrographolide, (E), Saponins, (F), Platycodin D, (G), Artesunate, (H), Deoxyelephantopin, (I), Artemisinin, (J), Albanol A, (K),  $\beta$ -Sitosterol, (L), Oridonin, (M), Curcumin, (N), Triptolide, (O), Isoegomaketone, (P), Chrysin, (Q), Coptisine.

**Table 1.** List of plant based anticancer compounds, source plant, cell line used and animal model used for in vivo.

Plant name	Active components	Cancer cell line applied to	Animal model applied
<i>Morus alba L.</i>	Albanol A	HL60	In-vitro
<i>Artemisia annua L</i>	Artemisinin	--	Sprague-rats
<i>Scutellariae baicalensis</i>	Baicalin	BGC-823, MGC-803/ Nalm-6, Daudi, NCI-H929	In-vitro
<b>Commercial</b>	Berberine	SCC-4	In-vitro
<i>Curcuma longa Linn</i>	Curcumin	HL-60, HT-29, MCF-7, MDA-MB-231, AK-5, Vv9V82 <sup>+</sup>	Rat
<i>Rhizoma Coptidis</i>	Coptisine	HCT-116	Balb/c mice
<i>Elephantopus scaber</i>	Deoxyelephantopin	N/A	Albino mice
<i>Scutellaria barbata</i>	Bezielle	MDAMB231, MCF10A,	In-vitro
<i>Perilla frutescens (L.)</i>	Isoegomaketone	DLD1	In-vitro
<i>Fagonia taeckholmiana</i>	Kaempferol	HEPG2, U251, MCF7	In-vitro
<i>Rabdosia rubescens</i>	Oridonin	SGC996, NOZ	Athymic nude mice
<i>Platycodon grandiflorum</i>	Platycodin D	U937, THP1, K562	In-vitro
<i>Asclepias curassavica Linn.</i>	$\beta$ -Sitosterol	COLO 320 DM, VERO	Albino Wistar rats

## CONCLUSIONS:

- Cancer is one of the major cause of death globally and is caused by alteration in regular function of a wide range of signal transduction, apoptotic and regulatory pathways.
- It cause millions of death globally with the majority of deaths in developing countries.
- Conventional therapies are associated with non-specificity and toxicity to normal cells.
- Affordability of cancer conventional therapies is a challenge specifically in developing countries of the world.
- The greatest recent advancement in cancer therapy is the use of plant-based anticancer agents as they are relatively more potent, safer, easily available and cheaper and many of the plant-based drugs have successfully cleared potency and safety tests in their clinical trials.
- Standardization of these potential drug candidate is required internationally under the guidelines of regulatory authorities that includes assessing their composition, potency, safety alongwith consistency in manufacturing.

## REFERENCES:

1. Rothman, N., S. Wacholder, N.E. Caporaso, et al., The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. *Biochim Biophys Acta*, 2001. 1471(2); p. C1-10.
2. American Cancer Society, Cancer facts & figures. 2008: American Cancer Society.
3. Tarver, T., Cancer facts & figures 2012. American cancer society (ACS) Atlanta, GA: American Cancer Society, 2012. 66 p., pdf. Available from. 2012, Taylor & Francis.
4. DeVita, N., S. Hellman S. Rosenberg, Cancer: Principles and practice of oncology (J Lippincott-Raven. Philadelphia, PA, 1997.
5. Ferlay, J., D.M. Parkin E. Steliarova-Foucher, Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer*, 2010. 46 (4); p. 765-81.



6th International Electronic Conference on  
Medicinal Chemistry  
1-30 November 2020

sponsored:



pharmaceuticals